{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:41:05Z","timestamp":1792644065828,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science Innovation and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Basque Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119316","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:45:33Z","timestamp":1789141533000},"page":"119316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring phosphorus substitution in chromeno[4,3-d]pyrido[1,2-a]pyrimidines: new insights into Topoisomerase 1 inhibition and cytotoxicity"],"prefix":"10.1016","volume":"320","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2995-6340","authenticated-orcid":false,"given":"Leyre","family":"Lopez-Aguileta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta R.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-9618","authenticated-orcid":false,"given":"Cinzia","family":"Tesauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endika","family":"Mart\u00edn-Encinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-3493","authenticated-orcid":false,"given":"Concepcion","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119316_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119316_bib2","series-title":"Topoisomerases and Cancer","author":"Pommier","year":"2012"},{"key":"10.1016\/j.ejmech.2026.119316_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/17460441.2022.2055545","article-title":"The design and discovery of topoisomerase 1 inhibitors as anticancer therapies","volume":"17","author":"Mart\u00edn-Encinas","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119316_bib4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase 1 inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119316_bib5","first-page":"5179","article-title":"Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase 1 poison","volume":"58","author":"Kohlhagen","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119316_bib6","first-page":"267","article-title":"Synthesis and biological evaluation of quinoline derivatives as antitumor agents","volume":"13","author":"Mendoza","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.889737","article-title":"Phosphonates and phosphonate prodrugs in medicinal chemistry: past successes and future prospects","volume":"10","author":"Kre\u010dmerov\u00e1","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100063","article-title":"Development and clinical application of phosphorus-containing drugs","volume":"8","author":"Yu","year":"2020","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119316_bib9","first-page":"1407","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"34","author":"Gettinger","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119316_bib10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40265-017-0811-4","article-title":"Brigatinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119316_bib11","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm100112j","article-title":"Medicinal chemist's guide to molecular interactions","volume":"53","author":"Bissantz","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2018.02.058","article-title":"Novel topoisomerase 1 inhibitors: syntheses and biological evaluation of phosphorus substituted quinoline derivatives with antiproliferative activity","volume":"149","author":"Alonso","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1021\/acs.joc.3c02220","article-title":"Aza-Povarov reaction: a method for the synthesis of fused tetracyclic chromeno[4,3-d]pyrido[1,2-a]pyrimidines","volume":"89","author":"Mart\u00edn-Encinas","year":"2024","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118782","article-title":"Synthesis and biological evaluation of novel fused pyridopyrimidine derivatives as topoisomerase 1 inhibitors and as potential antitumor agents: promising results in lung, ovary and gastric cancer","volume":"310","author":"Lopez-Aguileta","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib15","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.1021\/acs.joc.1c01413","article-title":"Phosphine oxides (\u2212POMe2) for medicinal chemistry: synthesis, properties, and applications","volume":"86","author":"Stambirskyi","year":"2021","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib16","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1002\/ejoc.201700258","article-title":"Reliable synthesis of phosphino- and phosphine sulfide-1,2,3,4-tetrahydroquinolines and phosphine sulfide quinolones","author":"Alonso","year":"2017","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib17","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.3390\/molecules26185637","article-title":"Selective esterification of phosphonic acids using triethyl orthoacetate","volume":"26","author":"Mazzini","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119316_bib18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1021\/jm900743c","article-title":"Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological and diagnostic potentials","volume":"53","author":"Colabufo","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119316_bib21","doi-asserted-by":"crossref","first-page":"10815","DOI":"10.1021\/bi980757r","article-title":"Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase 1 catalysis","volume":"37","author":"Lisby","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119316_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0378-4347(96)00152-1","article-title":"Separation and functional analysis of eukaryotic DNA topoisomerases by chromatography and electrophoresis","volume":"684","author":"Knudsen","year":"1996","journal-title":"J. Chromatogr. B Biomed. Appl."},{"issue":"3.3.1\u20133.3.27","key":"10.1016\/j.ejmech.2026.119316_bib23","article-title":"Topoisomerase assays","volume":"57","author":"Nitiss","year":"2012","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119316_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112843","article-title":"One molecule two goals: a selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells","volume":"208","author":"Contino","year":"2020","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:25:05Z","timestamp":1792643105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":22,"alternative-id":["S0223523426007610"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119316","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring phosphorus substitution in chromeno[4,3-d]pyrido[1,2-a]pyrimidines: new insights into Topoisomerase 1 inhibition and cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119316"}}